vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»vsp-1374Research ArticleОБЗОРЫ ЛИТЕРАТУРЫLITERATURE REVIEWПОЗАКОНАЗОЛ — НОВЫЙ АЗОЛЬНЫЙ АНТИМИКОТИК ШИРОКОГО СПЕКТРА ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ИНВАЗИВНЫХ МИКОЗОВPOSACONAZOLE — NEW AZOLE BROAD-SPECTRUM ANTIFUNGAL AGENT FOR PREVENTION AND TREATMENT OF INVASIVE MYCOSESКлимкоН.Н.KlimkoN.N.Санкт-Петербургская медицинская академия последипломного образованияРоссияSt. Petersburg Medical Academy of post-graduation EducationRussian Federation20082210201572Вопросы современной педиатрии93100Copyright © Климко Н., 20082008Климко Н.Klimko N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/1374ReferencesClark T.A, Hajjeh R.A. Recent trends in the epidemiology of invasive mycoses. Curr. Opin. Infect. Dis. 2002; 15: 569–574.Clark T.A, Hajjeh R.A. Recent trends in the epidemiology of invasive mycoses. Curr. Opin. Infect. Dis. 2002; 15: 569–574.Hayes-Lattin B, Maziarz RT. Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders. Leuk Lymphoma. 2004; 45: 669–680.Hayes-Lattin B, Maziarz RT. Update in the epidemiology, prophylaxis, and treatment of fungal infections in patients with hematologic disorders. Leuk Lymphoma. 2004; 45: 669–680.Климко Н.Н., Веселов А.В. Новые препараты для лечения инвазивных микозов. Клиническая микробиология, антимикробная химиотерапия. 2003; 5: 342–353.Климко Н.Н., Веселов А.В. Новые препараты для лечения инвазивных микозов. Клиническая микробиология, антимикробная химиотерапия. 2003; 5: 342–353.Dodds Ashley E., Alexander B. Posaconazole. Drugs Today. 2005; 41 (6): 393–400.Dodds Ashley E., Alexander B. Posaconazole. Drugs Today. 2005; 41 (6): 393–400.НОКСАФИЛ. Инструкция по медицинскому применению препарата. 2007.НОКСАФИЛ. Инструкция по медицинскому применению препарата. 2007.Groll A., Walsh T. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert. Rev. Anti Infect. Ther. 2005; 3 (4): 467–487.Groll A., Walsh T. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert. Rev. Anti Infect. Ther. 2005; 3 (4): 467–487.Boucher H., Groll A., Chiou C. et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs. 2004; 64 (18): 1997–2020.Boucher H., Groll A., Chiou C. et al. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs. 2004; 64 (18): 1997–2020.Andes D., Marchillo K., Conklin R. et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother. 2004; 48 (1): 137–142.Andes D., Marchillo K., Conklin R. et al. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother. 2004; 48 (1): 137–142.Pfaller M., Messer S., Hollis R. et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002; 46 (4): 1032–1037.Pfaller M., Messer S., Hollis R. et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother. 2002; 46 (4): 1032–1037.Sabatelli F., Patel R., Mann P. et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006; 50 (6): 2009–2015.Sabatelli F., Patel R., Mann P. et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother. 2006; 50 (6): 2009–2015.Torres-Narbona M., Guinea J., Martinez-Alarcon J. et al. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38–A, Sensititre Yeast One, and the Etest. Antimicrob. Agents Chemother. 2007; 51 (3): 1126–1129.Torres-Narbona M., Guinea J., Martinez-Alarcon J. et al. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38–A, Sensititre Yeast One, and the Etest. Antimicrob. Agents Chemother. 2007; 51 (3): 1126–1129.Torres H., Hachem R., Chemaly R. et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis. 2005; 12: 775–785.Torres H., Hachem R., Chemaly R. et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis. 2005; 12: 775–785.Antachopoulos C., Walsh T. New agents for invasive mycoses in children. Curr. Opin. Pediatr. 2005; 17 (1): 78–87.Antachopoulos C., Walsh T. New agents for invasive mycoses in children. Curr. Opin. Pediatr. 2005; 17 (1): 78–87.Barchiesi F., Spreghini E., Santinelli A. et al. Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob Agents Chemother. 2007; 51 (1): 73–77.Barchiesi F., Spreghini E., Santinelli A. et al. Posaconazole prophylaxis in experimental systemic zygomycosis. Antimicrob Agents Chemother. 2007; 51 (1): 73–77.Courtney R., Pai S., Laughlin M. et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 2003; 47 (9): 2788–2795.Courtney R., Pai S., Laughlin M. et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 2003; 47 (9): 2788–2795.Krieter P., Flannery B., Musick T. et al. Disposition of posaconazole following single dose oral administration in healthy subjects. Antimicrob. Agents Chemother. 2004; 48 (9): 3543–3551.Krieter P., Flannery B., Musick T. et al. Disposition of posaconazole following single dose oral administration in healthy subjects. Antimicrob. Agents Chemother. 2004; 48 (9): 3543–3551.Ullmann A., Cornely O., Burchardt A. et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 2006; 50 (2): 658–666.Ullmann A., Cornely O., Burchardt A. et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 2006; 50 (2): 658–666.Conte J.R., Golden J.A., Krishna G. et al. Intra pulmonary ppharmacokinetics-pharmacodynamics of posaconazole. 3 Advancer Against Aspergillosis. 2008.Conte J.R., Golden J.A., Krishna G. et al. Intra pulmonary ppharmacokinetics-pharmacodynamics of posaconazole. 3 Advancer Against Aspergillosis. 2008.Wexler D., Courtney R., Richards W. et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur. J. Pharm. Sci. 2004; 21 (5): 645-653.Wexler D., Courtney R., Richards W. et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur. J. Pharm. Sci. 2004; 21 (5): 645-653.Sansone-Parsons A., Krishna G., Simon J. et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob. Agents Chemother. 2007; 51 (2): 495–502.Sansone-Parsons A., Krishna G., Simon J. et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob. Agents Chemother. 2007; 51 (2): 495–502.Naggapan V., Deresinski S. Posaconazole: a broad-spectrum triazole antifungal agent. Clin. Infect Dis. 2007; 45: 1610–1617.Naggapan V., Deresinski S. Posaconazole: a broad-spectrum triazole antifungal agent. Clin. Infect Dis. 2007; 45: 1610–1617.Krishna G., Sansone–Parsons A., Martinho M. et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob. Agents Chemother. 2007; 51 (3): 812–818.Krishna G., Sansone–Parsons A., Martinho M. et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob. Agents Chemother. 2007; 51 (3): 812–818.Ullmann A., Cornely O. Antifungal prophylaxis for invasive mycoses in high risk patients. Curr. Opin. Infect. Dis. 2006; 19 (6): 571–576.Ullmann A., Cornely O. Antifungal prophylaxis for invasive mycoses in high risk patients. Curr. Opin. Infect. Dis. 2006; 19 (6): 571–576.Cornely O., Maertens J., Winston D. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 2007; 356 (4): 348–359.Cornely O., Maertens J., Winston D. et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 2007; 356 (4): 348–359.Ullmann A., Lipton J., Vesole D. et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 2007; 356 (4): 335–347.Ullmann A., Lipton J., Vesole D. et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 2007; 356 (4): 335–347.Keating G. Posaconazole. Drugs. 2005; 65 (11): 1553–1567.Keating G. Posaconazole. Drugs. 2005; 65 (11): 1553–1567.Pitisuttithum P., Negroni R., Graybill J. et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J. Antimicrob. Chemother. 2005; 56 (4): 745–755.Pitisuttithum P., Negroni R., Graybill J. et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J. Antimicrob. Chemother. 2005; 56 (4): 745–755.Walsh T., Raad I., Patterson T. et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. CID. 2007; 44 (1): 2–12.Walsh T., Raad I., Patterson T. et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. CID. 2007; 44 (1): 2–12.Tobon A., Arango M., Fernandez D. et al. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. CID. 2003; 36 (11): 1488–1491.Tobon A., Arango M., Fernandez D. et al. Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. CID. 2003; 36 (11): 1488–1491.Greenberg R., Mullane K., van Burik J. et al. Posaconazole as salvage therapy for Zygomycosis. Antimicrob. Agents Chemother. 2006; 50 (1): 126–133.Greenberg R., Mullane K., van Burik J. et al. Posaconazole as salvage therapy for Zygomycosis. Antimicrob. Agents Chemother. 2006; 50 (1): 126–133.Van Burik J., Hare R., Solomon H. et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. CID. 2006; 42 (7): 61–65.Van Burik J., Hare R., Solomon H. et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. CID. 2006; 42 (7): 61–65.Rutar T., Cockerham K. Periorbital zygomycosis (mucormycosis) treated with posaconazole. Am. J. Ophthalmol. 2006; 142 (1): 187–188.Rutar T., Cockerham K. Periorbital zygomycosis (mucormycosis) treated with posaconazole. Am. J. Ophthalmol. 2006; 142 (1): 187–188.Page R., Schwiesow J. Hilts A. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. Pharmacotherapy. 2007; 27 (2): 290–298.Page R., Schwiesow J. Hilts A. Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature. Pharmacotherapy. 2007; 27 (2): 290–298.Raad I., Hachem R., Herbrecht R. et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. CID. 2006; 42 (10): 1398–1403.Raad I., Hachem R., Herbrecht R. et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. CID. 2006; 42 (10): 1398–1403.Tu E., McCartney D., Beatty R. et al. Successful Treatment of Resistant Ocular Fusariosis With Posaconazole (SCH-56592). Am. J. Ophthalmol. 2007; 143 (2): 222–227.Tu E., McCartney D., Beatty R. et al. Successful Treatment of Resistant Ocular Fusariosis With Posaconazole (SCH-56592). Am. J. Ophthalmol. 2007; 143 (2): 222–227.Restrepo A., Tobon A., Clark B. et al. Salvage treatment of histoplasmosis with posaconazole. J. Infect. 2007; 54 (4): 319–327.Restrepo A., Tobon A., Clark B. et al. Salvage treatment of histoplasmosis with posaconazole. J. Infect. 2007; 54 (4): 319–327.Notheis G., Tarani L., Costantino F. et al. Posaconazole for treatment of refractory invasive fungal disease. Mycoses. 2006; 1: 37–41.Notheis G., Tarani L., Costantino F. et al. Posaconazole for treatment of refractory invasive fungal disease. Mycoses. 2006; 1: 37–41.De Decker K., Van Poucke S., Wojciechowski M. et al. Successful use of posaconazole in a pediatric case of fungal necrotizing fasciitis. Pediatr. Crit Care Med. 2006; 7 (5): 482–485.De Decker K., Van Poucke S., Wojciechowski M. et al. Successful use of posaconazole in a pediatric case of fungal necrotizing fasciitis. Pediatr. Crit Care Med. 2006; 7 (5): 482–485.Sorensen J., Becker M., Porto L. et al. Rhinocerebral zygomycosis in a young girl undergoing allogeneic stem cell transplantation for severe aplastic anaemia. Mycoses. 2006; 49: 31–36.Sorensen J., Becker M., Porto L. et al. Rhinocerebral zygomycosis in a young girl undergoing allogeneic stem cell transplantation for severe aplastic anaemia. Mycoses. 2006; 49: 31–36.Chan Y., Goldwater P., Saxon B. Successful treatment of cutaneous and subcutaneous zygomycosis in an immunosuppressed patient with aplastic anaemia. J. Paediatr. Child Health. 2007; 43 (1–2): 87–89.Chan Y., Goldwater P., Saxon B. Successful treatment of cutaneous and subcutaneous zygomycosis in an immunosuppressed patient with aplastic anaemia. J. Paediatr. Child Health. 2007; 43 (1–2): 87–89.Raad I., Graybill J., Bustamante A. et al. Safety of long term oral posaconazole use in the treatment of refractory invasive fungal infections. CID. 2006; 42 (12): 1726–1734.Raad I., Graybill J., Bustamante A. et al. Safety of long term oral posaconazole use in the treatment of refractory invasive fungal infections. CID. 2006; 42 (12): 1726–1734.Walsh T.J., Anaissie E.J., Denning D.W. et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Disieases Society of America. Clin. Infect. Dis. 2008; 46: 327–360.Walsh T.J., Anaissie E.J., Denning D.W. et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Disieases Society of America. Clin. Infect. Dis. 2008; 46: 327–360.NCCN Clinical Practice Guidelines in Oncology. 2007. V.1. Prevention and Treatment of Cancer Related Infections. www.nccn.org.NCCN Clinical Practice Guidelines in Oncology. 2007. V.1. Prevention and Treatment of Cancer Related Infections. www.nccn.org.Maertens J.A., Frèreb P., Lass-Flör C. et al. Primary antifungal prophylaxis in leukemia patients. Eur. J. Cancer. 2007; 5: 43–49.Maertens J.A., Frèreb P., Lass-Flör C. et al. Primary antifungal prophylaxis in leukemia patients. Eur. J. Cancer. 2007; 5: 43–49.
The authors declare that there are no conflicts of interest present.